Biogen said on Friday it has gained global rights to privately held Vanqua Bio's experimental drug for up to $1.06 billion to ...

Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the ...

Biogen and partner UCB recently announced upcoming presentations at the American College of Rheumatology 2025 conference highlighting positive Phase 3 data for dapirolizumab pegol in treating systemic ...

During the webinar, Unbuzzd CEO John Duffy, Advisor Jason Sawyer, Medical Director Dr. Eric Hoskins, and Board Co-Chair Gerry David, former CEO of Celsius, will discuss the current investment ...

Bristol Myers Squibb have extended their research collaboration aimed at designing and optimizing small-molecule drugs for ...

Making a lot of money is within your reach if you've got the right skills. Here are some high-demand jobs that allow you to ...

ProMIS Neurosciences, Inc. , a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that Slanix ...

Now, by analyzing thousands of proteins found in the blood, scientists at UC San Francisco have created the clearest picture ...

With ads everywhere for pro- or pre-biotic foods and supplements, most people are familiar with the gut microbiome—the ...

Researchers have traced the earliest stages of multiple sclerosis (MS), showing that the immune system begins attacking the brain up to seven years before diagnosis.

New study shows oral microbiome imbalance and reduced salivary hypotaurine may contribute to neuroinflammation in relapsing-remitting MS.